Category
HTA
Health technology assessment is how payers and governments decide whether a new medicine, device or diagnostic is worth funding. Our HTA coverage follows appraisals, methods guidance and agency decisions across major markets, and what they mean for the companies and patients on the other side of them.
402 articles in this topic.
Articles in this category
11/12/2026
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%
A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.
Read Article →
11/12/2026
The EU HTA Regulation: What Latin America Can Learn
A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.
Read Article →
11/10/2026
Neuquén Health Technology Assessment Agency: What Law 3563 Sets Up
Law 3563 creates a Neuquén health technology assessment agency. Guadalupe Montero explains how it will weigh safety, benefit, equity and budget impact.
Read Article →
11/10/2026
Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November
The Enzutrix patent dispute goes to South Africa's Constitutional Court on 23 November 2026. UC and Astellas are pursuing damages over the generic prostate cancer drug, while Eurolab argues the patent was never validly obtained. #SyenzaNews #MarketAccess
Read Article →
11/9/2026
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs
CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess
Read Article →
11/9/2026
Medicare drug price negotiation: CMS sets permanent rules
The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess
Read Article →
11/6/2026
Refixia Nonacog Beta Pegol: INFARMED Recommends Funding for Children Under 12 With Haemophilia B
INFARMED recommends public funding for Refixia nonacog beta pegol in children under 12 with haemophilia B, based on two single-arm trials. #SyenzaNews #MarketAccess
Read Article →
11/6/2026
Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit
The G-BA has found no proven added benefit for dupilumab in chronic spontaneous urticaria, compared with omalizumab plus second-generation H1 antihistamines.
Read Article →
11/4/2026
EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment
The EMA mid-year report 2026 records 485 scientific advice requests in the first half, the first joint clinical assessment under the HTA Regulation and progress on the new pharmaceutical law. #SyenzaNews #MarketAccess
Read Article →
11/3/2026
Second Cochlear Implant Now Covered for Adults in the Netherlands
The Dutch health institute Zorginstituut Nederland has concluded that a second cochlear implant for adults with severe hearing loss in both ears belongs in the basic health package. #SyenzaNews #MarketAccess
Read Article →
11/3/2026
Generic lenacapavir HIV prevention gets FDA tentative approval
Dr. Reddy's has FDA tentative approval for generic lenacapavir HIV prevention, priced at US$40 per person per year across 120 countries. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
11/2/2026
PBS Strategic Agreements: What Government and Industry Told Patients Before the Next Deal
Australia's PBS strategic agreements with the medicines industry expire on 30 June 2027. At a 23 October webinar, the health department, GBMA and Medicines Australia explained what the deals cover, how patients can feed in, and where industry says they have fallen short on access. #SyenzaNews #MarketAccess #HTA #PBS #Australia
Read Article →